Renal transplant imaging using magnetic resonance angiography with a nonnephrotoxic contrast agent

Transplantation

Volumn 96, Issue 1, 2013, Pages 91-96

  Bashir, Mustafa R ^a   Jaffe, Tracy A ^a   Brennan, Todd V ^a   Patel, Uptal D ^a   Ellis, Matthew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Feraheme; Ferumoxytol; Kidney transplant; Magnetic resonance angiography; MRA

Indexed keywords

FERUMOXYTOL;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANASTOMOSIS STENOSIS; ANGIOPLASTY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTRAST ENHANCEMENT; CONVENTIONAL ANGIOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GRAFT PATENCY; GRAFT RECIPIENT; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY ARTERY STENOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MEDICAL RECORD REVIEW; PATIENT SAFETY; PRIORITY JOURNAL; RENOGRAPHY; VASCULAR PATENCY;

ADULT; AGED; CONTRAST MEDIA; FEMALE; FERROSOFERRIC OXIDE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY TRANSPLANTATION; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PRIMARY GRAFT DYSFUNCTION; RETROSPECTIVE STUDIES; VASCULAR PATENCY;

EID: 84879838831     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318295464c     Document Type: Article

References (30)

1. Audard V, Matignon M, Hemery F, et al. Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty. Am J Transplant 2006; 6: 95.
2. Pouria S, State OI, Wong W, et al. CMV infection is associated with transplant renal artery stenosis. QJM 1998; 91: 185.
3. Humar A, Matas AJ. Surgical complications after kidney transplantation. Semin Dial 2005; 18: 505.
4. Bruno S, Remuzzi G, Ruggenenti P. Transplant renal artery stenosis. J Am Soc Nephrol 2004; 15: 134.
5. Loubeyre P, Abidi H, Cahen R, et al. Transplanted renal artery: detection of stenosis with color Doppler US. Radiology 1997; 203: 661.
6. Steubl D, Papachristou E, Wolf P, et al. Doppler-ultrasound measurements in renal allografts depend on the patient's body position. Vasa 2012; 41: 114.
7. Persson PB, Hansell P, Liss P. Pathophysiology of contrast mediuminduced nephropathy. Kidney Int 2005; 68: 14.
8. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000.
9. Grobner T. GadoliniumVa specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104.
10. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008; 43: 141.
11. Lu M, Cohen MH, Rieves D, et al. FDA report: ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease. Am J Hematol 2010; 85: 315.
12. Qiu D, Zaharchuk G, Christen T, et al. Contrast-enhanced functional blood volume imaging (CE-fBVI): enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol. Neuroimage 2012; 62: 1726.
13. Stabi KL, Bendz LM. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography. Ann Pharmacother 2011; 45: 1571.
14. Hamilton BE, Nesbit GM, Dosa E, et al. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging. AJR Am J Roentgenol 2011; 197: 981.
15. Li W, Tutton S, Vu AT, et al. First-pass contrast-enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)Ybased blood pool agent.JMagn Reson Imaging 2005; 21: 46.
16. Cohan RH, DavenportMS, Dillman JR, Ellis JH, Hartman RP, Herts BR, et al. ACR Manual on ContrastMedia v. 8. 2012. Available from: http://www.acr.org~/ media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/FullManual. pdf.
17. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrastinduced nephropathy. JAMA 2006; 295: 2765.
18. Gedroyc WM, Negus R, al-Kutoubi A, et al. Magnetic resonance angiography of renal transplants. Lancet 1992; 339: 789.
19. Loubeyre P, Cahen R, Grozel F, et al. Transplant renal artery stenosis. Evaluation of diagnosis with magnetic resonance angiography compared with color duplex sonography and arteriography. Transplantation 1996; 62: 446.
20. Leung DA, Hagspiel KD, Angle JF, et al. MR angiography of the renal arteries. Radiol Clin North Am 2002; 40: 847.
21. Luk SH, Chan JH, Kwan TH, et al. Breath-hold 3D gadoliniumenhanced subtraction MRA in the detection of transplant renal artery stenosis. Clin Radiol 1999; 54: 651.
22. Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med 2012; 3: 77.
23. Qiu D, Zaharchuk G, Christen T, et al. Contrast-enhanced functional blood volume imaging (CE-fBVI): enhanced sensitivity for brain activation in humans using the ultrasmall superparamagnetic iron oxide agent ferumoxytol. Neuroimage 2012; 62: 1726.
24. Sigovan M, Gasper W, Alley HF, et al. USPIO-enhanced MR angiography of arteriovenous fistulas in patients with renal failure. Radiology 2012; 265: 584.
25. Administration USFaD. MedWatch: Feraheme (Ferumoxytol) Injection. 2011 (cited 2012 October 22); Available from: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/ucm235636.htm.
26. Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011; 196: W138.
27. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 2010; 30: 15.
28. McCullough BJ, Kolokythas O, Maki JH, et al. Ferumoxytol in clinical practice: implications for MRI. J Magn Reson Imaging 2013; 37: 1476.
29. Bremerich J, Bilecen D, Reimer P. MR angiography with blood pool contrast agents. Eur Radiol 2007; 17: 3017.
30. Karabulut N, Elmas N. Contrast agents used in MR imaging of the liver. Diagn Interv Radiol 2006; 12: 22.